Treatment of functional bowel disorders: Is there room for antibiotics?

Digestion

Volumn 73, Issue SUPPL. 1, 2006, Pages 38-46

  Corazza, Gino Roberto ^a   Di Stefano, Michele ^a   Scarpignato, Carmelo ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Antimicrobials; Functional bowel disorders; Irritable bowel syndrome; Rifaximin; Small intestine bacterial overgrowth

Indexed keywords

ACTIVATED CARBON; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN; CHLORAMPHENICOL; COTRIMOXAZOLE; LINCOMYCIN; METRONIDAZOLE; NORFLOXACIN; RIFAXIMIN; TETRACYCLINE;

ABDOMINAL PAIN; ANOREXIA; BACTERIAL OVERGROWTH; BLOATING; CARBOHYDRATE INTAKE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIETARY FIBER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTEROPATHY; FLATULENCE; HUMAN; HYDROGEN BREATH TEST; INTESTINE FLORA; LASSITUDE; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; COLONIC DISEASES, FUNCTIONAL; HUMANS; TREATMENT OUTCOME;

EID: 33644510788     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089778     Document Type: Review

References (58)

1. Dotevall G, Svedlund J, Sjodin I: Symptoms in irritable bowel syndrome. Scand J Gastroenterol Suppl 1982;79:16-19.
2. Lembo T, Naliboff B, Munakata J, Fullerton S, Saba L, Tung S, Schmulson M, Mayer EA: Symptom and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999;94:1320-1326.
3. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL: Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000;45:1166-1171.
4. Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. Br Med J 1978;ii:653-654.
5. Maxton DG, Morris JA, Whorwell PJ: Ranking of symptoms by patients with irritable bowel syndrome. Br Med J 1989;299:1138.
6. Cameron IC, Stoddard JE, Treacy PJ, Patterson J, Stoddard CJ: Long-term symptomatic follow-up after Lind fundoplication. Br J Surg 2000;87:362-373.
7. Laine S, Rantala A, Gullichsen R, Ovaska J: laparoscopic vs. conventional Nissen fundoplication. A prospective randomized study. Surg Endosc 1997;11:441-444.
8. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR: Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000;14:1001-1008.
9. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR: Rifaximin versus chlortetracycline in the short-term treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2000;14:551-556.
10. Gorbach SL: Probiotics and gastrointestinal health. Am J Gastroenterol 2000;95:S1-S4.
11. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ: Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003;17:655-659.
12. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR: A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
13. O'Sullivan MA, O'Morain CA: Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:294-301.
14. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238.
15. Caldarella MP, Serra J, Azpiroz F, Malagelada JR: Prokinetic effects in patients with intestinal gas retention. Gastroenterology 2002;122:1748-1755.
16. Lin HC: Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-858.
17. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):43-47.
18. Levitt MD, Furne J, Olsson S: The relation of passage of gas and abdominal bloating to colonic gas production. Ann Intern Med 1996;124:422-424.
19. Distrutti E, Azpiroz F, Soldevilla A, Malagelada JR: Gastric wall tension determines perception of gastric distension. Gastroenterology 1999;116:1035-1042.
20. 2) excretion to detect carbohydrate malabsorption. J Lab Clin Med 1970;75:937-945.
21. Strocchi A, Ellis C, Levitt MD: Reproducibility of measurements of trace gas concentrations in expired air. Gastroenterology 1991;101:175-179.
22. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR: Hypersensitivity to colonic gas in the pathophysiology of symptoms in functional patients. Gastroenterology 2004;126(suppl 2):A378.
23. Frissora CL, Koch KL: Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005;7:264-271.
24. Vernia P, Ricciardi MR, Frandina C, Bilotta T, Frieri G: Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactose-free diet. Ital J Gastroenterol 1995;27:117-121.
25. Cappello G, Marzio L: Rifaximin in patients with lactose intolerance. Dig Liver Dis 2005;37:316-319.
26. King CE, Toskes PP: Small intestine bacterial overgrowth. Gastroenterology 1979;76:1035-1055.
27. Banwell JG, Kistler LA, Giannella RA, Weber FL, Lieber A, Powell DE: Small intestinal bacterial overgrowth syndrome. Gastroenterology 1981;80:834-845.
28. Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G: The diagnosis of small bowel bacterial overgrowth. Gastroenterology 1990;98:302-309.
29. Nayak AK, Karnad DR, Abraham P, Mistry FP: Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'. Indian J Gastroenterol 1997;16:137-139.
30. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-419.
31. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-3506.
32. Sellin JH, Hart R: Glucose malabsorption associated with rapid intestinal transit. Am J Gastroenterol 1992;87:584-589.
33. Lupascu A, Gabrielli M, Lauritano C, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-1160.
34. McCallum R, Schultz C, Sostarich S: Evaluating the role of small intestinal bacterial overgrowth in diarrhea predominant irritable bowel syndrome patients using the glucose breath test. Gastroenterology 2005;128(suppl 2):A460.
35. Rumessen JJ, Nordgaard-Andersen I, Gudmand-Hoyer E: Carbohydrate malabsorption: quantification by methane and hydrogen breath tests. Scand J Gastroenterol 1994;29:826-832.
36. Myo-Khin, Bolin TD, Khin-Mar-Oo, Tin-Oo, Kyaw-Hla S, Thein-Myint T: Ineffectiveness of breath methane excretion as a diagnostic test for lactose malabsorption. J Pediatr Gastroenterol Nutr 1999;28:474-479.
37. Corazza GR, Benati G, Strocchi A, Malservisi S, Gasbarrini G: The possible role of breath methane measurement in detecting carbohydrate malabsorption. J Lab Clin Med 1994;124:695-700.
38. Bond JH Jr, Engel RR, Levitt MD: Factors influencing pulmonary methane excretion in man. An indirect method of studying the in situ metabolism of the methane-producing colonic bacteria. J Exp Med 1971;133:572-588.
39. Flourie B, Etanchaud F, Florent C, Pellier P, Bouhnik Y, Rambaud JC: Comparative study of hydrogen and methane production in the human colon using caecal and faecal homogenates. Gut 1990;31:684-685.
40. Levitt MD, Duane WC: Floating stools - flatus versus fat. N Engl J Med 1972;286:973-975.
41. Simrén M, Ringstrom G, Agerforz P, Bjornsson ES, Abrahamsson H, Stolzer PO: Small intestinal bacterial overgrowth is not of major importance in the irritable bowel syndrome. Gastroenterology 2003;124(suppl 1):A163.
42. Di Stefano M, Corazza GR: Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. Chemotherapy 2005;51(suppl 1):103-109.
43. Kahn IJ, Jeffries GH, Sleisenger MH: Malabsorption in intestinal scleroderma: correction by antibiotics. N Engl J Med 1966;274:1339-1344.
44. Goldstein F, Wirts CW, Kramer S: The relationship of afferent loop stasis and bacterial flora to the production of postgastrectomy steatorrhea. Gastroenterology 1961;40:47-54.
45. Bjorneklett A, Fausa O, Midtvedt T: Bacterial overgrowth in jejunal and ileal disease. Scand J Gastroenterol 1983;18:289-298.
46. Joiner KA, Gorbach SL: Antimicrobial therapy of digestive diseases. Clin Gastroenterol 1979;8:3-35.
47. Bouhnik Y, Alain S, Attar A, Flourie B, Raskine L, Sanson-Le Pors MJ, Rambaud JC: Bacterial population contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999;94:1327-1331.
48. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
49. Jiang ZD, DuPont HL: Rifaximin: In vitro and in vivo antibacterial activity - a review. Chemotherapy 2005;51(suppl 1):67-72.
50. Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR: Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind loop syndrome. Aliment Pharmacol Ther 2005;21:985-992.
51. Gorbach SL, Tabaqchali S: Bacteria, bile and the small bowel. Gut 1969;10:963-972.
52. Goldstein F, Wirts CW, Kowlessar OD: Diabetic diarrhea and steatorrhea. Ann Intern Med 1970;72:215-218.
53. Eisborg L: Malabsorption in small intestinal diverticulosis treated with a low dosage sulphonamide-trimethoprim. Dan Med Bull 1977;24:33-35.
54. Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y: Antibiotic efficacy in small intestinal bacterial overgrowth related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999;117:794-797.
55. Trespi E, Ferrieri A: Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin 1999;15:47-52.
56. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-35.
57. Pimentel M, Spark S, Kong Y, Wade R, Kane AV: Rifaximin, a non-absorbable antibiotic, improves symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Am J Gastroenterol 2005;100(suppl):S324.
58. Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R: Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005;100:2560-2568.